Gaze Contingent Attentional Reinforcement in Major Depressive Disorder
Key facts
- Where
- Tel Aviv, IsraelSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07364981, who can take part
Where in Israel
- Tel Aviv UniversityTel Aviv, IsraelNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tel Aviv University
- Trial code
- NCT07364981
- Record updated
- 23 January 2026
- Original description
The main objective of this randomized controlled trial is to evaluate whether a gaze-contingent feedback task using negative reinforcement can serve as an effective attention-modification procedure and contribute to the treatment of Major Depressive Disorder (MDD).Read full original descriptionShow less
Gaze Contingent Attentional Reinforcement Treatment of MDD
The main objective of this randomized controlled trial is to evaluate whether a gaze-contingent feedback task using negative reinforcement can serve as an effective attention-modification procedure and contribute to the treatment of Major Depressive Disorder (MDD).
Inclusion: Primary diagnosis of MDD; MADRS>=7; Normal or corrected-t-normal vision.
Exclusion: Pharmacological treatment if not stabilized for at least three months or concurrent psychotherapy; Severe alcohol or cannabis use disorder, and/or any severity of other substance use disorder (exepct nicotine use); Current unstable or untreated medical illness; Current or past organic mental disorder, seizure or brain injury; Present or past psychosis, manic or hypomanic episode, PTSD; High suicidal ideation or behavior; Eye-tracking calibration difficulties; Post-ECT treatment.